argus

ALEMBIC PHARMACEUTICALS LIMITED

NSE: APLLTDINE901L0101816,596 Cr

Timeline

Time (IST)TypeMEventSrc
16 Dec, 04:02 pmAlembic Pharmaceuticals Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Companynse
11 Dec, 11:54 amAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%".nse
11 Dec, 11:53 amAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
01 Dec, 06:41 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Managementbse
01 Dec, 06:41 pmAlembic Pharmaceuticals Limited has informed the Exchange about change in Managementnse
15 Nov, 09:15 amAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
15 Nov, 09:10 amAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 15, 2025, titled "Alembic Pharmaceuticals Limited announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg".nse
13 Nov, 11:53 amAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dexlansoprazole Delayed-Release Capsules, 30 mg and 60 mg.".nse
13 Nov, 11:45 amAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
11 Nov, 12:08 pmAlembic Pharmaceuticals Limited has informed the Exchange about Transcriptnse
11 Nov, 12:07 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
07 Nov, 03:05 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
07 Nov, 03:04 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 07, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System".nse
07 Nov, 12:37 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 07, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.".nse
07 Nov, 12:35 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
06 Nov, 09:49 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015'.nse
04 Nov, 06:01 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
04 Nov, 05:57 pmAlembic Pharmaceuticals Limited has informed the Exchange about Link of Recordingnse
04 Nov, 03:25 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a revised press release dated November 04, 2025, titled "Revised Press Release for the Q2 FY 26 Results".nse
04 Nov, 03:23 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)bse
04 Nov, 02:47 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
04 Nov, 02:45 pmAlembic Pharmaceuticals Limited has informed the Exchange about Investor Presentationnse
04 Nov, 02:43 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
04 Nov, 02:41 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Please find attached herewith the Press Release for the Q2 FY 26 Results".nse
04 Nov, 02:39 pmAlembic Pharmaceuticals Ltd - 533573 - Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2025.bse
04 Nov, 02:33 pmAlembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.nse
04 Nov, 02:28 pmAlembic Pharmaceuticals Ltd - 533573 - Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2025bse
04 Nov, 02:27 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 04, 2025.nse
29 Oct, 11:58 amAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
29 Oct, 11:58 amAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 29, 2025, titled "Alembic Pharmaceuticals Limited announces USFDA Final Approval for Ticagrelor Tablets, 60 mg".nse
23 Oct, 12:30 pmAlembic Pharmaceuticals Ltd - 533573 - Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2025bse
18 Oct, 06:02 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
18 Oct, 05:56 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 18, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL (Single-Dose and Multiple-Dose Vials)".nse
01 Oct, 09:52 amAlembic Pharmaceuticals Limited has informed the Exchange about General Updates - Intimation for change of email address of the Registrar and Share Transfer Agent ( RTA ) of the Companynse
25 Sept, 12:37 pmAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
25 Sept, 12:36 pmAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 25, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg".nse
13 Sept, 03:52 pmAlembic Pharmaceuticals Limited has informed the Exchange about receipt of Establishment Inspection Report (EIR) for its API - I & API - II Facility located at Panelavnse
09 Sept, 10:50 amAlembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 09, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-Dose Prefilled Syringe".nse
09 Sept, 10:50 amAlembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse